Wed, 03 Feb 2016 15:00:00 GMT ~ Lixte Biotechnology Holdings, Inc.'s Lead Compound LB-100 Reported to Rapidly Improve Symptoms in a Rodent Model of Depression
[Marketwired] - Lixte Biotechnology Holdings, Inc. announced that neuroscientists at the French Institute of Health and Medical Research using a mouse model of depression have identified protein phosphatase 2A as a potential ...
Mon, 25 Jan 2016 15:30:00 GMT ~ Lixte Completes Private Placement of Convertible Preferred Stock
[Marketwired] - Lixte Biotechnology Holdings, Inc. announced today that a major shareholder has purchased $1,750,000 of Convertible Preferred stock. If fully converted, this purchase would convert to 2,187,500 common ...
Tue, 05 Jan 2016 01:05:00 GMT ~ Lixte Biotechnology Holdings, Inc. Announces Exclusive Licensing Of Their Lead Anti-Cancer Compound LB-100 For Potential Treatment Of Hepatocellular Carcinoma In Asia To Taipei Medical University
[PR Newswire] - EAST SETAUKET, N.Y., Jan. 5, 2016 /PRNewswire/ -- Lixte Biotechnology Holdings, Inc. (LIXT) announced last week that it has granted an exclusive license of its lead anti-cancer compound, LB-100, for treatment of hepatocellular carcinoma (HCC) in Asia to Taipei Medical University (TMU). Under the license, Taipei Medical University will determine the effectiveness of LB-100 against HCC in clinical trials conducted in compliance with both Taiwanese and American regulatory requirements. TMU will pay milestone and royalty payments to Lixte. Both parties recognize that development of improved therapy for HCC has been very challenging and that success cannot be guaranteed.
Link: http://www.otcmarkets.com/stock/LIXT/company-info Ticker: $LIXT OTC Market Place: OTCQB CIK code: 0001335105 Company name: Lixte Biotechnology Holdings, Inc. Company website: http://www.lixte.com Incorporated In: DE, USA
Business Description: Lixte Biotechnology Holdings, Inc. is a clinical-stage public pharmaceutical company dedicated to discovering drugs for more effective treatments for cancer. Lixte has identified molecular signaling pathways altered in disease states and designed compounds that can safely target them in animal models. The current drug portfolio includes inhibitors of protein phosphatases that are critical to cell division and DNA damage repair and inhibitors of protein deacetylases that regulate pathways of gene expression and protein degradation.Less >>
$LIXT share structure
## source: otcmarkets.com
Market Value: $11,968,954 a/o Feb 03, 2016 Shares Outstanding: 47,875,814 a/o Nov 03, 2015 Float: Not Available Authorized Shares: 100,000,000 a/o Dec 30, 2014 Par Value: 0.001 $LIXT extra dd links
Company name: Lixte Biotechnology Holdings, Inc. Company website: http://www.lixte.com
News 
Market Data 
Discover 
